FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089749215> ?p ?o ?g. }

• W3089749215 endingPage "306" @default.
• W3089749215 startingPage "299" @default.
• W3089749215 abstract "The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score≥50% advanced non–small cell lung cancer patients treated with first-line pembrolizumab according to the presence/absence of brain metastases. A total of 282 patients were included, of whom 56 had brain metastases that were treated with upfront local radiation therapy in 80.3% of cases. The overall response rate was 39.2% and 44.4% in patients with and without brain metastases ( P =0.48), respectively, while intracranial response rate and intracranial disease control rate were 67.5% and 85.0%, respectively. The median time-to-treatment failure (TTF) and overall survival (OS) were 4.2 and 9.9 months versus 10.8 and 26.5 months for patients with and without brain metastases ( P =0.06 and 0.05, respectively). Drug discontinuation rate due to treatment-related adverse events was 10.7% and 10.2% in patients with and without brain metastases, respectively. Multivariate analysis showed that baseline steroids was an independent predictor for a worse OS ( P <0.001), while performance status (PS)≥2 was an independent predictor for a poorer TTF ( P <0.001) and OS ( P <0.001). In patients with brain metastases, only PS ≥2 was predicted for a worse TTF ( P =0.02) and OS ( P =0.03). Pembrolizumab has activity against brain metastases from non–small cell lung cancers with programmed death-ligand 1≥50%. Presence of brain metastases per se does not appear to be prognostic, and PS ≥2 seems to be the only factor associated with a worse outcome in patients with brain metastases." @default.
• W3089749215 created "2020-10-08" @default.
• W3089749215 creator A5001684767 @default.
• W3089749215 creator A5003736175 @default.
• W3089749215 creator A5004251271 @default.
• W3089749215 creator A5005810267 @default.
• W3089749215 creator A5006525898 @default.
• W3089749215 creator A5011289747 @default.
• W3089749215 creator A5021158045 @default.
• W3089749215 creator A5023893215 @default.
• W3089749215 creator A5030211144 @default.
• W3089749215 creator A5033351253 @default.
• W3089749215 creator A5034761732 @default.
• W3089749215 creator A5035764851 @default.
• W3089749215 creator A5044610238 @default.
• W3089749215 creator A5047645174 @default.
• W3089749215 creator A5048322584 @default.
• W3089749215 creator A5057105147 @default.
• W3089749215 creator A5059919842 @default.
• W3089749215 creator A5064542874 @default.
• W3089749215 creator A5064636994 @default.
• W3089749215 creator A5069668842 @default.
• W3089749215 creator A5078917021 @default.
• W3089749215 creator A5086743021 @default.
• W3089749215 creator A5090452503 @default.
• W3089749215 date "2020-09-25" @default.
• W3089749215 modified "2023-10-03" @default.
• W3089749215 title "Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%" @default.
• W3089749215 cites W1913378555 @default.
• W3089749215 cites W2373606074 @default.
• W3089749215 cites W2416791964 @default.
• W3089749215 cites W2527905628 @default.
• W3089749215 cites W2772183668 @default.
• W3089749215 cites W2774847863 @default.
• W3089749215 cites W2807369789 @default.
• W3089749215 cites W2888599070 @default.
• W3089749215 cites W2905870269 @default.
• W3089749215 cites W2908622615 @default.
• W3089749215 cites W2912571746 @default.
• W3089749215 cites W2935577863 @default.
• W3089749215 cites W2939507240 @default.
• W3089749215 cites W2952666958 @default.
• W3089749215 cites W2955483669 @default.
• W3089749215 cites W2965540807 @default.
• W3089749215 cites W2969539132 @default.
• W3089749215 cites W2990357315 @default.
• W3089749215 cites W2996784175 @default.
• W3089749215 cites W3000489007 @default.
• W3089749215 cites W3010178462 @default.
• W3089749215 cites W3013243565 @default.
• W3089749215 cites W3014209163 @default.
• W3089749215 cites W3029424640 @default.
• W3089749215 cites W3036338598 @default.
• W3089749215 doi "https://doi.org/10.1097/cji.0000000000000340" @default.
• W3089749215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32991393" @default.
• W3089749215 hasPublicationYear "2020" @default.
• W3089749215 type Work @default.
• W3089749215 sameAs 3089749215 @default.
• W3089749215 citedByCount "17" @default.
• W3089749215 countsByYear W30897492152021 @default.
• W3089749215 countsByYear W30897492152022 @default.
• W3089749215 countsByYear W30897492152023 @default.
• W3089749215 crossrefType "journal-article" @default.
• W3089749215 hasAuthorship W3089749215A5001684767 @default.
• W3089749215 hasAuthorship W3089749215A5003736175 @default.
• W3089749215 hasAuthorship W3089749215A5004251271 @default.
• W3089749215 hasAuthorship W3089749215A5005810267 @default.
• W3089749215 hasAuthorship W3089749215A5006525898 @default.
• W3089749215 hasAuthorship W3089749215A5011289747 @default.
• W3089749215 hasAuthorship W3089749215A5021158045 @default.
• W3089749215 hasAuthorship W3089749215A5023893215 @default.
• W3089749215 hasAuthorship W3089749215A5030211144 @default.
• W3089749215 hasAuthorship W3089749215A5033351253 @default.
• W3089749215 hasAuthorship W3089749215A5034761732 @default.
• W3089749215 hasAuthorship W3089749215A5035764851 @default.
• W3089749215 hasAuthorship W3089749215A5044610238 @default.
• W3089749215 hasAuthorship W3089749215A5047645174 @default.
• W3089749215 hasAuthorship W3089749215A5048322584 @default.
• W3089749215 hasAuthorship W3089749215A5057105147 @default.
• W3089749215 hasAuthorship W3089749215A5059919842 @default.
• W3089749215 hasAuthorship W3089749215A5064542874 @default.
• W3089749215 hasAuthorship W3089749215A5064636994 @default.
• W3089749215 hasAuthorship W3089749215A5069668842 @default.
• W3089749215 hasAuthorship W3089749215A5078917021 @default.
• W3089749215 hasAuthorship W3089749215A5086743021 @default.
• W3089749215 hasAuthorship W3089749215A5090452503 @default.
• W3089749215 hasConcept C121608353 @default.
• W3089749215 hasConcept C126322002 @default.
• W3089749215 hasConcept C143998085 @default.
• W3089749215 hasConcept C167135981 @default.
• W3089749215 hasConcept C197934379 @default.
• W3089749215 hasConcept C2776256026 @default.
• W3089749215 hasConcept C2777701055 @default.
• W3089749215 hasConcept C2778164965 @default.
• W3089749215 hasConcept C2778715236 @default.
• W3089749215 hasConcept C2779013556 @default.
• W3089749215 hasConcept C2780057760 @default.
• W3089749215 hasConcept C71924100 @default.

• next